The Vaccine Debate: What Is The Evidence?

by admin

We all hear about it in the news seemingly every day. Swine flu propaganda and fear generation is everywhere. Have you ever stopped to think about why that is? The answer is: Fear Sells.

They call it the “vaccine industry” for a reason. It is industrious. By creating fear and putting some publicly well known doctor’s name behind it, the vaccine industry makes billions of dollars per year by scaring you into getting the shot. The same fear makes them billions more by scaring parents into taking their children in to receive over 35 shots, containing 113 different kinds of disease particles, 59 different chemicals, 4 types of animal cells/DNA, and human DNA from aborted fetal tissue before the age of 10. Do you want this injected into yourself or your baby?

According to the International Medical Council on Vaccination (IMCV), vaccines have documented associations with:

* Allergies
* Asthma
* Arthritis
* Autism
* Acid Reflux
* Cancer
* Diabetes
* Sudden Infant Death Syndrome
* A long list of neurological and autoimmune diseases.

» Read more: The Vaccine Debate: What Is The Evidence?

Posted in Articles

Will the Chimigen Vaccine Stop Bird Flu, Anthrax and Hepatitis?

by admin

We interviewed Dr. Rajan George, Adjunct Faculty of the University of Alberta’s Pharmacy and Pharmaceutical Sciences Department. Dr. George is also Vice President of Research and Development for the Division of Infection Diseases of ViRexx Medical Co. As part of the team of University of Alberta scientists, a therapeutic vaccine is now being developed which may inoculate against Hepatitis, Anthrax and Avian Flu H5N1. The team of scientists includes internationally renowned Dr. Lorne Tyrrell, former Dean of Medicine at the University of Alberta, and Dr. Antoine Noujaim, Professor Emeritus of the University of Alberta.

All three scientists are affiliated with ViRexx Medical Corp. On March 31st, the company announced it had entered into research collaboration with Defence Research and Development Canada – Suffield (DRDC Suffield) to carry out research to evaluate ViRexx’s proprietary Chimigen(TM) vaccine platform for biodefense applications. On April 6th, the company announced it had recruited procurement advocate Frank Rapoport of McKenna Long & Aldridge to pursue acquisitions of development contracts from the U.S. Department of Defense and NIH with a particular focus on the potential of the Chimigen(TM) technology in addressing biodefense and pandemic threats. The company cited two of major targets would be, but not limited to, H5N1 avian flu and anthrax.

» Read more: Will the Chimigen Vaccine Stop Bird Flu, Anthrax and Hepatitis?

Posted in Articles